38 results about "Influenza antibody" patented technology

The present invention relates to the intersection of the fields of immunology and protein engineering, and particularly to antigens and vaccines useful in prevention of infection by influenza virus. Provided are recombinant protein antigens, compositions, and methods for the production and use of such antigens and vaccine compositions.

The invention discloses a method for detecting a system for quickly screening a fever pathogen, and mainly relates to detection of a tuberculosis antibody, a flu antibody, a bird flu antibody, a plague antibody and an SARS antibody in blood serum. The chip mainly comprises coding microspheres, a coating antigen, a detection antibody, a biotinylated antibody and a streptavidin-phycoerythrin. The method comprises the following steps that: the coating antigen and the coding microshperes are coupled; the detection antibody is respectively coupled with the corresponding microspheres in separate specificity; the red laser excites the classified fluorescence on the spherical substrate; the type is determined according to different colors of the spherical substrates, wherein the biotinylated antibody is combined with the detection antibody; and the streptavidin-phycoerythrin is combined with the biotin of the detection antibody captured by the microshperes; the green laser excites the phycoerythrin, the number of report fluorescence molecules combined on the spherical substrate is measured, and the number is used for indirectly determining the content of the detection antibody combined onthe spherical substrate, so that whether the pathogen infection exists is determined, and the aim of quickly screening the fever pathogen is achieved.

Humanized recombinant and monoclonal antibodies specific for the ectodomain of the influenza virus M2 ion channel protein are disclosed. The antibodies of the invention have anti-viral activity and may be useful as anti-viral therapeutics and/or prophylactic/vaccine agents for inhibiting influenza virus replication and for treating individuals infected with influenza.

The present invention provides novel human anti-influenza antibodies and related compositions and methods. These antibodies are used in the diagnosis and treatment of influenza infection.

The invention relates to an scFv antibody for resisting H5N1 type highly-pathogenic avian influenza and an application thereof. A light chain amino acid sequence is shown as SEQIDNo: 1; a heavy chain amino acid sequence is shown as SEQIDNo: 2; a light chain nucleotide sequence is shown as SEQIDNo: 3; and a heavy chain nucleotide sequence is shown as SEQIDNo: 4. The scFv antibody for resisting the H5N1 type highly-pathogenic avian influenza is applied to the preparation of a medicine for resisting the H5N1 type avian influenza virus. Proven by protection tests of embryonated eggs, the 4F5 antibody has a 100% protective rate on prevention of the avian source and human source H5N1 type avian influenza virus infection, and the 4F5 antibody has a 100% protective rate on treatment of the avian source H5N1 type avian influenza virus infection. The highest protective rate on treatment of the human source H5N1 type highly-pathogenic avian influenza virus infection is 62.5%.

The invention discloses a protein suspension chip for synchronously detecting various antibodies in serum sample and a preparation method and a using method thereof. The method has the advantages of good detection capacity, high sensitivity, strong specificity and wide dynamic range, and an open detection modular platform of the protein suspension chip for detecting microbial antibodies represented by West Nile antibody, Francisella tularensis antibody, dengue fever antibody and influenza antibody is established.

The present invention provides novel human anti-influenza antibodies and related compositions and methods. These antibodies are used in the diagnosis and treatment of influenza infection.

This invention belongs to disease dialogue field outside virus and its antigen rapid test method, which relates to flu virus film protein M1 and M2 with N end height conversion MSLLTEVET and its abnormal meter level to process dialogue case through decoration to process flu antigen level test; using MSLLTEVET and its abnormal meter antigen through decoration to process dialogue agent case for flu virus test.

The invention provides avian H9 subtype avian influenza virus antibody colloidal gold test paper and test card. The avian H9 subtype avian influenza virus antibody colloidal gold test paper and test card can detect the immune level of various birds and are wide in application range, high in specificity, high in sensitivity, easy to operate and short in consumed time. The test paper comprises a sample pad, a gold-labeled pad and a nitrocellulose membrane which are sequentially connected, wherein the gold-labeled pad is wrapped with a colloidal gold label of a monoclonal antibody, namely anti-mouse IgY Fc CH3-CH4; and a detection line close to one end of the gold-labeled pad and a quality control line away from one end of the gold-labeled pad are arranged on the nitrocellulose membrane, thedetection line is wrapped with an AIV-HA19 recombinant protein, the quality control line is wrapped with a second antibody, and the DNA sequence for encoding the AIV-HA19 recombinant protein is shownas SEQ ID NO.1.

The invention relates to a new quantitative detection method and a product for detecting influenza antibody in a serum sample. The method of the invention has good detection capability, high sensitivity, strong specificity and wide dynamic range. The invention establishes an open detection modularised platform of pathogenic bacteria antibody protein suspension chip detection with the influenza antibody as a representative.

Vaccines that elicit broadly protective anti-influenza antibodies. The vaccines comprise nanoparticles that display HA trimers from Group 2 influenza virus on their surface. The nanoparticles are fusion proteins comprising a monomeric subunit (e.g., ferritin) joined to stabilized stem regions of Group 2 influenza virus HA proteins. The fusion proteins self-assemble to form the HA-displaying nanoparticles. Also provided are fusion proteins, and nucleic acid molecules encoding such proteins, and assays using nanoparticles of the invention to detect anti-influenza antibodies.